南财智讯1月30日电，科兴制药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 13500万元—17500万元，同比预增328.83%—455.89%；预计2025年全年归属于上市公司股东的扣除非 经常性损益的净利润为5000万元—7000万元，同比预增41.83%—98.56%。本期业绩变化的主要原因： 2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 ...

Group 1 - The company expects a net loss attributable to shareholders of the parent company for 2025 to be between -180 million to -160 million yuan, representing an increase in loss of 66.49 million to 86.49 million yuan compared to the previous year, which is a year-on-year increase in loss of 71.12% to 92.51% [1] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -185 million to -165 million yuan, with an increase in loss of 58.78 million to 78.78 million yuan compared to the previous year, reflecting a year-on-year increase in loss of 55.33% to 74.16% [1] - The company has completed the enrollment of subjects for the Phase III clinical trial of the quadrivalent influenza virus split vaccine (for children) and has finished the vaccination process, with serum currently undergoing inspection at the National Medical Products Administration [1] Group 2 - Due to equipment failures and differences in consumable batches, the company has decided not to sell certain in-process and finished products, adhering to a cautious principle [2] - The quadrivalent influenza virus split vaccine has a shelf life of 12 months from the date of production, and any unadministered vaccines at the end of each flu season must be disposed of according to relevant laws and regulations [2] - The company has made provisions for asset impairment and inventory write-offs totaling approximately 41.99 million yuan, based on market research and historical return rates [2]

智通财经APP讯，中慧生物-B(02627)发布公告，中国国家药品监督管理局已批准本集团针对所有年龄组 别的三价流感病毒亚单位疫苗的新药申请。 截至本公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 ...

Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its trivalent influenza virus subunit vaccine, making it the first and only approved vaccine for all age groups in China [1] Group 1 - The vaccine is a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and a lower risk of adverse reactions [1]

华熙生物公告，预计2025年年度实现归属于母公司所有者的净利润人民币27,000.00万元到32,000.00万 元，与上年同期（法定披露数据）相比，将增加9,573.26万元到14,573.26万元，同比增加54.93%到 83.63%。公司上年同期归属于母公司所有者的净利润为17,426.74万元，归属于母公司所有者的扣除非 经常性损益的净利润为10,727.20万元，比较基数较小，导致公司业绩变动幅度较大。 ...

Core Viewpoint - The announcement highlights that Zhonghui Biotech-B (02627.HK) has received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine, making it the first and only vaccine approved for all age groups in China [1] Group 1: Product Approval - The trivalent influenza virus subunit vaccine is now approved for all age groups, marking a significant milestone for the company [1] - This vaccine is the first and only one in China that has been approved for the entire population and all dosage levels [1] Group 2: Product Advantages - The vaccine represents a major upgrade over traditional virus split vaccines, offering comprehensive protection [1] - It features high purity of antigen components and a lower risk of adverse reactions [1]

| | 2022年 | 2023年 | 2024年 | 2025年H | | --- | --- | --- | --- | --- | | 信达生物营业收入(亿元) | 45. 56 | 62.06 | 94. 22 | 59. 53 | | 销售开支 | 25.91 | 31.01 | 43. 47 | 23.75 | | 行政开支 | 8.35 | 7.5 | 7.38 | | | 研发开支(亿元) | 28. 71 | 22.28 | 26.81 | | | 信达生物归母净利润 | -21.79 | -10.28 | -0.9463 | 8.34 | | 最高市值 | 858.83 | 864.03 | 904.80 | 1892.89 | | 最低市值 | 322.71 | 473.66 | 491.01 | 497.08 | | 股本数(亿) | 17.35 | 17.35 | 17.35 | 17.35 | | 股价最高 | 49.5 | 49.8 | 52.15 | 109.1 | | 股价最低 | 18.6 | 27.3 | 28.3 | 28.65 | 来源：理忱视野 在《从Biotech ...

证券日报网讯1月30日，天康生物（002100）在互动平台回答投资者提问时表示，截至2026年1月20日收 盘，公司股份持有人数为62780户。 ...

Core Viewpoint - The actual controller of Zhaoyan New Drug, Zhou Zhiwen, has terminated his plan to reduce shareholdings in the company, having sold a total of 14,979,000 shares within a specified period, resulting in significant cash proceeds. Group 1: Shareholding and Reduction Plan - Zhou Zhiwen held 74,725,981 shares before the reduction plan, representing 9.9704% of the total share capital [1] - The reduction plan was first disclosed on December 30, 2025, allowing for a maximum reduction of 14,980,000 shares, which is 20.0466% of his holdings and 1.99873% of the total share capital [1] - The actual reduction occurred from January 22 to January 28, 2026, with a total of 14,979,000 shares sold [2] Group 2: Financial Details of the Reduction - The shares were sold at a price range of 34.78 to 42.19 yuan per share, resulting in total proceeds of 567,606,657.9 yuan [1][2] - The reduction was completed with only 1,000 shares remaining unsold, achieving a reduction ratio of 1.99894% [2] - Following the reduction, Zhou Zhiwen's remaining shareholding is 59,746,981 shares, which is 7.9732% of the total share capital [2] Group 3: Historical Context - Since November 5, 2020, Zhou Zhiwen has cumulatively reduced his holdings by 14,113,200 shares, realizing approximately 915 million yuan in cash [2] - The actual controllers of Zhaoyan New Drug are identified as Feng Yuxia and Zhou Zhiwen, a couple [3]

每经AI快讯，奥浦迈1月30日晚间发布公告称，2025年度，公司合并报表范围内计提资产减值损失和信 用减值损失合计1912.81万元，对公司2025年度合并报表利润总额影响金额为1912.81万元。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） ...